Janux Therapeutics GAAP EPS of -$0.51 beats by $0.16

2026-02-26 17:05:19 ET More on Janux Therapeutics Janux Therapeutics, Inc. (JANX) Shareholder/Analyst Call - Slideshow Janux Therapeutics: Downgrading To 'Hold' Rating After Latest Updated Phase 1 JANX007 mCRPC Data Janux Falls Back To Earth As 'Best-In-Class' Hopes Confront Phase 1 Reality (Rating Downgrade) Bristol Myers inks licensing deal with Janux for cancer therapy Here are the most and least likely M&A targets in biotech, according to Truist Read the full article on Seeking Alpha For further details see: Janux Therapeutics GAAP EPS of -$0.51 beats by $0.16